FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: A propensity score-adjusted analysis from two randomized clinical trials

C. Cremolini, F. Loupakis, G. Masi, S. Lonardi, Cristina Granetto, M.L. Mancini, S. Chiara, R. Moretto, D. Rossini, Stefano Vitello, Giacomo Allegrini, G. Tonini, F. Bergamo, G. Tomasello, M. Ronzoni, A. Buonadonna, S. Bustreo, C. Barbara, L. Boni, A. Falcone

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: A propensity score-adjusted analysis from two randomized clinical trials'. Together they form a unique fingerprint.

Medicine & Life Sciences